Literature DB >> 31535280

The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.

Fernando Antonanzas1, Carmelo Juárez-Castelló2, Reyes Lorente2, Roberto Rodríguez-Ibeas2.   

Abstract

OBJECTIVE: The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders'  perceptions.
METHODS: We conducted a systematic literature search in MEDLINE from 2000 to April 2019, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology, and completed it with a manual search of other publications (mainly grey literature). The search was restricted to publications with English abstracts; the initial identification of articles was restricted to the title, abstract and key words fields. The geographical scope was not restricted.
RESULTS: Over 20 studies proposed different taxonomies of risk-sharing contracts, which can be summarised as financial and paying-for-performance agreements. Theoretical studies modelling the incentives to implement risk-sharing agreements are scarce; they addressed different types of contracts and regulatory contexts, characterizing the drug prices and the optimal strategies of the involved agents. Empirical studies describing specific agreements are abundant and referred to different geographical contexts; however, few articles showed the economic results and assessed the value of such contracts. Stakeholders' perceptions of risk-sharing contracting were favourable, but little is known about the economic and clinical advantages of specific agreements. Whether risk-sharing contracts have yielded the desired results for healthcare systems remains uncertain.
CONCLUSION: Risk-sharing contracts are increasingly used, although the lack of transparency and aggregated registries makes it difficult to learn from these experiences and assess their impact on healthcare systems.

Year:  2019        PMID: 31535280     DOI: 10.1007/s40273-019-00838-w

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  52 in total

1.  [Innovative patient access schemes for the adoption of new technology: risk-sharing agreements].

Authors:  Jaime Espín; Juan Oliva; José Manuel Rodríguez-Barrios
Journal:  Gac Sanit       Date:  2010-11-11       Impact factor: 2.139

2.  The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.

Authors:  Gregory S Zaric; Bin Xie
Journal:  Value Health       Date:  2009 Jul-Aug       Impact factor: 5.725

3.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Access with evidence development schemes: a framework for description and evaluation.

Authors:  Christopher J McCabe; Tania Stafinski; Richard Edlin; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Acuerdos de Riesgo Compartido: Lecciones Para su Diseño e Implementación a la Luz de la Experiencia Internacional.

Authors:  Daniela María Paredes Fernández; Rony Christian Lenz Alcayaga
Journal:  Value Health Reg Issues       Date:  2019-03-12

6.  Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.

Authors:  Christiane Maskineh; Soumana C Nasser
Journal:  Value Health Reg Issues       Date:  2018-06-22

7.  Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.

Authors:  Steven G Morgan; Paige A Thomson; Jamie R Daw; Melissa K Friesen
Journal:  Health Policy       Date:  2013-06-25       Impact factor: 2.980

Review 8.  Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.

Authors:  Josh J Carlson; Katharine S Gries; Kai Yeung; Sean D Sullivan; Louis P Garrison
Journal:  Appl Health Econ Health Policy       Date:  2014-06       Impact factor: 2.561

9.  Italian risk-sharing agreements on drugs: are they worthwhile?

Authors:  Livio Garattini; Alessandro Curto; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2015-01

10.  Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?

Authors:  Fernando Antoñanzas; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

View more
  11 in total

1.  Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Authors:  Aris Angelis; Huseyin Naci; Allan Hackshaw
Journal:  Pharmacoeconomics       Date:  2020-12       Impact factor: 4.981

2.  A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.

Authors:  Nasuh C Buyukkaramikli; Peter Wigfield; Men Thi Hoang
Journal:  Eur J Health Econ       Date:  2020-09-08

3.  Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.

Authors:  Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; László Szilberhorn; Tamás Zelei; Balázs Nagy; Rositsa Koleva-Kolarova; Apostolos Tsiachristas; Sarah Wordsworth; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2021-04-16       Impact factor: 4.981

Review 4.  Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision.

Authors:  Simone A Huygens; Matthijs M Versteegh; Stefan Vegter; L Jan Schouten; Tim A Kanters
Journal:  Pharmacoeconomics       Date:  2021-02-19       Impact factor: 4.981

5.  Central European journal of operations research (CJOR) "operations research applied to health services (ORAHS) in Europe: general trends and ORAHS 2020 conference in Vienna, Austria".

Authors:  Roberto Aringhieri; Patrick Hirsch; Marion S Rauner; Melanie Reuter-Oppermanns; Margit Sommersguter-Reichmann
Journal:  Cent Eur J Oper Res       Date:  2021-12-10       Impact factor: 2.345

Review 6.  The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe.

Authors:  Natalie Bohm; Sarah Bermingham; Frank Grimsey Jones; Daniela C Gonçalves-Bradley; Alex Diamantopoulos; Jessica R Burton; Hamish Laing
Journal:  Pharmacoeconomics       Date:  2021-09-04       Impact factor: 4.981

7.  Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.

Authors:  Lucía Romero-Pinel; Laura Bau; Elisabet Matas; Isabel León; Roser Juvany; Ramon Jódar; Antonio Martínez-Yélamos; Sergio Martínez-Yélamos
Journal:  PLoS One       Date:  2022-04-29       Impact factor: 3.240

8.  Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.

Authors:  Olina Efthymiadou; Panos Kanavos
Journal:  BMC Health Serv Res       Date:  2022-08-20       Impact factor: 2.908

9.  Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.

Authors:  Mohamed Gad; Ahmed Salem; Wija Oortwijn; Ruaraidh Hill; Brian Godman
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

10.  How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements.

Authors:  Gregory S Zaric
Journal:  MDM Policy Pract       Date:  2021-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.